Gefitinib and erlotinib are orally administered epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) used for the treatment of non–small-cell lung cancer (NSCLC) in patients with activated mutations of the EGFR gene [3-6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.